ESHRE Guideline: management of women with premature ovarian insufficiency

European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Lisa Webber, L Webber, M. Davies, Melanie Davies, Richard A. Anderson, R Anderson, J Bartlett, J.R. Bartlett, D. Braat, B Cartwright, R Cifkova, Renata Cífková, S de Muinck Keizer-Schrama, S de Muinck Keizer‐Schrama, E Hogervorst, Eef Hogervorst, F Janse, L Liao, V Vlaisavljevic, C Zillikens, Carola Zillikens, N Vermeulen
Human Reproduction · 2016 · vol. 31(5) , pp. 926–937 · doi:10.1093/humrep/dew027 · PMID:27008889 · W2309700868
Guideline OA: green CC0 ⤵ 66 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This guideline offers 99 recommendations for diagnosing and managing premature ovarian insufficiency (POI) based on a systematic literature review and expert consensus, acknowledging data limitations.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

STUDY QUESTION: What is the optimal management of women with premature ovarian insufficiency (POI) based on the best available evidence in the literature? SUMMARY ANSWER: The guideline development group (GDG) formulated 99 recommendations answering 31 key questions on the diagnosis and treatment of women with POI. WHAT IS KNOWN ALREADY: NA. STUDY DESIGN, SIZE, DURATION: This guideline was produced by a multidisciplinary group of experts in the field using the methodology of the Manual for ESHRE Guideline Development, including a thorough systematic search of the literature, quality assessment of the included papers up to September 2014 and consensus within the guideline group on all recommendations. The GDG included a patient representative to ensure input from women with POI. After finalization of the draft, the European Society for Human Reproduction and Embryology (ESHRE) members and professional organizations were asked to review the guideline. PARTICIPANTS/MATERIALS, SETTING, METHODS: NA. MAIN RESULTS AND THE ROLE OF CHANCE: The guideline provides 17 recommendations on diagnosis and assessment of POI and 46 recommendations on the different sequelae of POI and their consequences for monitoring and treatment. Furthermore, 24 recommendations were formulated on hormone replacement therapy in women with POI, and two on alternative and complementary treatment. A chapter on puberty induction resulted in five recommendations. LIMITATIONS, REASONS FOR CAUTION: The main limitation of the guideline is that, due to the lack of data, many of the recommendations are based on expert opinion or indirect evidence from studies on post-menopausal women or women with Turner Syndrome. WIDER IMPLICATIONS OF THE FINDINGS: Despite the limitations, the guideline group is confident that this document will be able to guide health care professionals in providing the best practice for managing women with POI given current evidence. Furthermore, the guideline group has formulated research recommendations on the gaps in knowledge identified in the literature searches, in an attempt to stimulate research on the key issues in POI. STUDY FUNDING/COMPETING INTERESTS: The guideline was developed and funded by ESHRE, covering expenses associated with the guideline meetings, with the literature searches and with the implementation of the guideline. The guideline group members did not receive payment. Dr Davies reports non-financial support from Novo Nordisk, outside the submitted work; the other authors had nothing to disclose. TRIAL REGISTRATION NUMBER: NA.

My notes (saved in your browser only)

MeSH descriptors

Primary Ovarian Insufficiency Adolescent Adult Female Hormone Replacement Therapy Humans Primary Ovarian Insufficiency Primary Ovarian Insufficiency Primary Ovarian Insufficiency Puberty Societies, Scientific

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (48)

Source provenance

openalex
last seen: 2026-05-11T05:01:01.489467+00:00
pubmed
last seen: 2026-10-08T21:17:32.889250+00:00
License: CC0 · commercial use OK